Form 4: Elevation Oncology Director Timothy Clackson Granted 35,000 Stock Options

Elevation Oncology, Inc. Director Timothy P. Clackson was granted 35,000 stock options with an exercise price of $0.3051, vesting on the one-year anniversary of the grant date.

Summary

• Timothy P. Clackson, a Director of Elevation Oncology, Inc. (ELEV), was granted 35,000 stock options.
• The transaction date for this grant was June 5, 2025.
• Each stock option has an exercise price of $0.3051.
• The options will vest as to 100% of the total shares on the one-year anniversary of the grant date, which is June 5, 2026.
• Vesting is contingent upon Mr. Clackson's continued provision of service to the Issuer on the vesting date.
• The expiration date for these stock options is June 4, 2035.
• Following this transaction, Mr. Clackson beneficially owns 35,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Slightly positive, as it represents a standard compensation practice that aligns director interests with shareholders, without indicating any negative operational or financial news.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term value creation.
• Stock options are a common and accepted form of compensation for directors, helping to attract and retain qualified board members.

Negatives

• The exercise of these options in the future could lead to a slight dilution of existing shareholders' equity, although the amount is relatively small.

Risks

• The value of the stock options is dependent on the future market price of Elevation Oncology's common stock; if the stock price does not exceed the exercise price of $0.3051, the options may not be exercised.
• The options are subject to a vesting condition, meaning they will only become exercisable if the director continues to provide service to the company for one year from the grant date.

Future Outlook

The stock options are set to vest on the one-year anniversary of the grant date, allowing the director to potentially acquire common stock at the specified exercise price, aligning future incentives with company performance.

Industry Context

Stock options are a standard component of executive and director compensation in the biotechnology sector, aiming to incentivize long-term performance and align interests with shareholders. This grant is consistent with typical compensation structures in the industry.

Comparison to Industry Standards

• The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industries, particularly for companies like Elevation Oncology that may be in development stages.
• The vesting schedule of 100% on the one-year anniversary is a straightforward approach to director compensation, often used to ensure continued board engagement.
• While specific comparable companies or projects are not detailed in this filing, the structure of this compensation aligns with general industry benchmarks for non-employee director equity grants, which typically involve options or restricted stock units to foster long-term alignment.

Corporate Governance

Related Party Transactions

• Grant of 35,000 stock options to Timothy P. Clackson, a Director of Elevation Oncology, Inc.

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also improved alignment of director's interests with shareholder value creation.
• Employees: No direct impact mentioned, but part of a broader compensation framework that may influence overall company culture and talent retention strategies.

Next Steps

• The stock options will vest on June 5, 2026, subject to the director's continued service.
• The director may choose to exercise the options at any time between the vesting date and the expiration date (June 4, 2035), provided the stock price is favorable.

Key Dates

Keywords

SEC Form 4, stock option grant, insider transaction, director compensation, Elevation Oncology, ELEV, equity compensation, beneficial ownership